Even if youre using a GLP-1 RA primarily to manage diabetes, weight loss is common, and along with it, some muscle mass loss is likely to occur
These are investigational peptides studied in preclinical models for tissue repair and resilience
References: Sugimoto K, Murakawa Y, Sima A
The FDA chose April Fools Day to issue an update clarifying its policies for compounders as the
one Published Research The SURMOUNT and SURPASS trial programs provide extensive published documentation: SURMOUNT-1 through SURMOUNT-4: Obesity indication trials SURPASS-1 through SURPASS-5: Diabetes indication trials Extensive real-world evidence from post-marketing surveillance Published literature across multiple populations and demographics Retatrutide: GLP-1 + GIP + Glucagon Retatrutide represents the most comprehensive receptor coverage, activating all three pathways that Mazdutide and Tirzepatide divide between them
Rajanahally S, Raheem O, Rogers M, et al